Mutations in BRCA2 and PALB2 in male breast cancer cases from the United States

Breast Cancer Research and Treatment

Volumn 126, Issue 3, 2011, Pages 771-778

  Ding, Yuan Chun ^a   Steele, Linda ^a   Kuan, Chih Jen ^b   Greilac, Scott ^c   Neuhausen, Susan L ^a  

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c PrimeGen Biotech LLC   (United States)

Author keywords

BRCA2; Genetic testing; Male breast cancer; PALB2

Indexed keywords

BRCA2 PROTEIN; GENOMIC DNA; PROTEIN PALB2; TUMOR PROTEIN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BRCA2 GENE; BREAST CANCER; BREAST CARCINOGENESIS; CANCER FAMILY; CANCER GRADING; CONTROLLED STUDY; FAMILY HISTORY; GENE MUTATION; GENETIC ASSOCIATION; HUMAN; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MALE BREAST CANCER; MOLECULAR PATHOLOGY; MULTIPLEX LIGATION DEPENDENT PROBE AMPLIFICATION; MUTATION RATE; MUTATIONAL ANALYSIS; PALB2 GENE; PHENOTYPE; PRIORITY JOURNAL; SEQUENCE ANALYSIS; SINGLE STRAND CONFORMATION POLYMORPHISM; UNITED STATES;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS, MALE; GENES, BRCA2; GENETIC PREDISPOSITION TO DISEASE; GENETIC TESTING; HUMANS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; MODELS, GENETIC; MUTATION; NUCLEAR PROTEINS; TUMOR SUPPRESSOR PROTEINS; UNITED STATES;

EID: 79954535293     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-010-1195-2     Document Type: Article

References (43)

1. Hecht JR, Winchester DJ (1994) Male breast cancer. Am J Clin Pathol 102(4 Suppl 1):S25-S30 (Pubitemid 24345580)
2. Stratton MR (1996) Recent advances in understanding of genetic susceptibility to breast cancer. Hum Mol Genet 5 Spec No:1515-1519
3. American Cancer Society. Breast Cancer Facts and Figures 2009-2010. Atlanta: American Cancer Society, Inc
4. Fentiman IS, Fourquet A, Hortobagyi GN (2006) Male breast cancer. Lancet 367(9510):595-604 (Pubitemid 43247575)
5. Antoniou AC, Easton DF (2006) Models of genetic susceptibility to breast cancer. Oncogene 25(43):5898-5905 (Pubitemid 44453445)
6. Evans DG, Susnerwala I, Dawson J, Woodward E, Maher ER, Lalloo F (2010) Risk of breast cancer in male BRCA2 carriers. J Med Genet. doi:10.1136/jmg.2009. 075176
7. Basham VM, Lipscombe JM, Ward JM, Gayther SA, Ponder BA, Easton DF, Pharoah PD (2002) BRCA1 and BRCA2 mutations in a population-based study of male breast cancer. Breast Cancer Res 4(1):R2 (Pubitemid 34097557)
8. Besic N, Cernivc B, de Greve J, Lokar K, Krajc M, Novakovic S, Zgajnar J, Teugels E (2008) BRCA2 gene mutations in Slovenian male breast cancer patients. Genet Test 12(2):203-209 (Pubitemid 351860434)
9. Couch FJ, Farid LM, DeShano ML, Tavtigian SV, Calzone K, Campeau L, Peng Y, Bogden B, Chen Q, Neuhausen S et al (1996) BRCA2 germline mutations in male breast cancer cases and breast cancer families. Nat Genet 13(1):123-125 (Pubitemid 126528243)
10. Csokay B, Udvarhelyi N, Sulyok Z, Besznyak I, Ramus S, Ponder B, Olah E (1999) High frequency of germ-line BRCA2 mutations among Hungarian male breast cancer patients without family history. Cancer Res 59(5):995-998 (Pubitemid 29135956)
11. Diez O, Cortes J, Domenech M, Pericay C, Brunet J, Alonso C, Baiget M (2000) BRCA2 germ-line mutations in Spanish male breast cancer patients. Ann Oncol 11(1):81-84 (Pubitemid 30084584)
12. Evans DG, Bulman M, Young K, Gokhale D, Lalloo F (2001) High detection rate for BRCA2 mutations in male breast cancer families from North West England. Fam Cancer 1(3-4):131-133
13. Friedman LS, Gayther SA, Kurosaki T, Gordon D, Noble B, Casey G, Ponder BA, Anton-Culver H (1997) Mutation analysis of BRCA1 and BRCA2 in a male breast cancer population. Am J Hum Genet 60(2):313-319 (Pubitemid 27058403)
14. Haraldsson K, Loman N, Zhang QX, Johannsson O, Olsson H, Borg A (1998) BRCA2 germ-line mutations are frequent in male breast cancer patients without a family history of the disease. Cancer Res 58(7):1367-1371 (Pubitemid 28193591)
15. Kwiatkowska E, Teresiak M, Filas V, Karczewska A, Breborowicz D, Mackiewicz A (2003) BRCA2 mutations and androgen receptor expression as independent predictors of outcome of male breast cancer patients. Clin Cancer Res 9(12): 4452-4459 (Pubitemid 37248403)
16. Mavraki E, Gray IC, Bishop DT, Spurr NK (1997) Germline BRCA2 mutations in men with breast cancer. Br J Cancer 76(11): 1428-1431 (Pubitemid 27501124)
17. Ottini L, Masala G, D'Amico C, Mancini B, Saieva C, Aceto G, Gestri D, Vezzosi V, Falchetti M, De Marco M et al (2003) BRCA1 and BRCA2 mutation status and tumor characteristics in male breast cancer: a population-based study in Italy. Cancer Res 63(2):342-347 (Pubitemid 36152491)
18. Ottini L, Rizzolo P, Zanna I, Falchetti M, Masala G, Ceccarelli K, Vezzosi V, Gulino A, Giannini G, Bianchi S et al (2009) BRCA1/BRCA2 mutation status and clinical-pathologic features of 108 male breast cancer cases from Tuscany: a population-based study in central Italy. Breast Cancer Res Treat 116(3):577-586
19. Struewing JP, Coriaty ZM, Ron E, Livoff A, Konichezky M, Cohen P, Resnick MB, Lifzchiz-Mercerl B, Lew S, Iscovich J (1999) Founder BRCA1/2 mutations among male patients with breast cancer in Israel. Am J Hum Genet 65(6):1800-1802 (Pubitemid 30468698)
20. Syrjakoski K, Kuukasjarvi T, Waltering K, Haraldsson K, Auvinen A, Borg A, Kainu T, Kallioniemi OP, Koivisto PA (2004) BRCA2 mutations in 154 Finnish male breast cancer patients. Neoplasia 6(5):541-545 (Pubitemid 39411091)
21. Thorlacius S, Sigurdsson S, Bjarnadottir H, Olafsdottir G, Jonasson JG, Tryggvadottir L, Tulinius H, Eyfjord JE (1997) Study of a single BRCA2 mutation with high carrier frequency in a small population. Am J Hum Genet 60(5):1079-1084 (Pubitemid 27194092)
22. Wolpert N, Warner E, Seminsky MF, Futreal A, Narod SA (2000) Prevalence of BRCA1 and BRCA2 mutations in male breast cancer patients in Canada. Clin Breast Cancer 1(1):57-63 discussion 64-55
23. Xia B, Dorsman JC, Ameziane N, de Vries Y, Rooimans MA, Sheng Q, Pals G, Errami A, Gluckman E, Llera J et al (2007) Fanconi anemia is associated with a defect in the BRCA2 partner PALB2. Nat Genet 39(2):159-161 (Pubitemid 46184344)
24. Xia B, Sheng Q, Nakanishi K, Ohashi A, Wu J, Christ N, Liu X, Jasin M, Couch FJ, Livingston DM (2006) Control of BRCA2 cellular and clinical functions by a nuclear partner, PALB2. Mol Cell 22(6):719-729
25. Rahman N, Seal S, Thompson D, Kelly P, Renwick A, Elliott A, Reid S, Spanova K, Barfoot R, Chagtai T et al (2007) PALB2, which encodes a BRCA2-interacting protein, is a breast cancer susceptibility gene. Nat Genet 39(2):165-167 (Pubitemid 46184346)
26. Erkko H, Xia B, Nikkila J, Schleutker J, Syrjakoski K, Mannermaa A, Kallioniemi A, Pylkas K, Karppinen SM, Rapakko K et al (2007) A recurrent mutation in PALB2 in Finnish cancer families. Nature 446(7133):316-319 (Pubitemid 46426155)
27. Foulkes WD, Ghadirian P, Akbari MR, Hamel N, Giroux S, Sabbaghian N, Darnel A, Royer R, Poll A, Fafard E et al (2007) Identification of a novel truncating PALB2 mutation and analysis of its contribution to early-onset breast cancer in French-Canadian women. Breast Cancer Res 9(6):R83
28. Garcia MJ, Fernandez V, Osorio A, Barroso A, Llort G, Lazaro C, Blanco I, Caldes T, de la Hoya M, Ramon YCT et al (2009) Analysis of FANCB and FANCN/PALB2 fanconi anemia genes in BRCA1/2-negative Spanish breast cancer families. Breast Cancer Res Treat 113(3):545-551
29. Tischkowitz M, Xia B, Sabbaghian N, Reis-Filho JS, Hamel N, Li G, van Beers EH, Li L, Khalil T, Quenneville LA et al (2007) Analysis of PALB2/FANCN-associated breast cancer families. Proc Natl Acad Sci USA 104(16):6788-6793 (Pubitemid 47175579)
30. Wilson E (1927) Probable inference, the law of succession, and statistical inference. J Am Stat Assoc 22:209-212
31. Easton DF, Deffenbaugh AM, Pruss D, Frye C, Wenstrup RJ, Allen-Brady K, Tavtigian SV, Monteiro AN, Iversen ES, Couch FJ et al (2007) A systematic genetic assessment of 1, 433 sequence variants of unknown clinical significance in the BRCA1 and BRCA2 breast cancer-predisposition genes. Am J Hum Genet 81(5):873-883 (Pubitemid 47580242)
32. Reid S, Schindler D, Hanenberg H, Barker K, Hanks S, Kalb R, Neveling K, Kelly P, Seal S, Freund M et al (2007) Biallelic mutations in PALB2 cause Fanconi anemia subtype FAN and predispose to childhood cancer. Nat Genet 39(2): 162-164 (Pubitemid 46184345)
33. Oliver AW, Swift S, Lord CJ, Ashworth A, Pearl LH (2009) Structural basis for recruitment of BRCA2 by PALB2. EMBO Rep 10(9):990-996
34. Ramensky V, Bork P, Sunyaev S (2002) Human non-synonymous SNPs: server and survey. Nucleic Acids Res 30(17): 3894-3900 (Pubitemid 35012462)
35. Ferrer-Costa C, Gelpi JL, Zamakola L, Parraga I, de la Cruz X, Orozco M (2005) PMUT: a web-based tool for the annotation of pathological mutations on proteins. Bioinformatics 21(14): 3176-3178 (Pubitemid 41418475)
36. Andrulis IL, Anton-Culver H, Beck J, Bove B, Boyd J, Buys S, Godwin AK, Hopper JL, Li F, Neuhausen SL et al (2002) Comparison of DNA- and RNA-based methods for detection of truncating BRCA1 mutations. Hum Mutat 20(1):65-73 (Pubitemid 34747718)
37. Jordanova A, Kalaydjieva L, Savov A, Claustres M, Schwarz M, Estivill X, Angelicheva D, Haworth A, Casals T, Kremensky I (1997) SSCP analysis: a blind sensitivity trial. Hum Mutat 10(1): 65-70 (Pubitemid 27298951)
38. Anglian Breast Cancer Study Group (2000) Prevalence and penetrance of BRCA1 and BRCA2 mutations in a population-based series of breast cancer cases. Br J Cancer 83(10): 1301-1308
39. Kim SW, Lee CS, Fey JV, Borgen PI, Boyd J (2005) Prevalence of BRCA2 mutations in a hospital based series of unselected breast cancer cases. J Med Genet 42(1):e5
40. Sy SM, Huen MS, Zhu Y, Chen J (2009) PALB2 regulates recombinational repair through chromatin association and oligomerization. J Biol Chem 284(27):18302-18310
41. Ng PC, Henikoff S (2001) Predicting deleterious amino acid substitutions. Genome Res 11(5):863-874 (Pubitemid 32447869)
42. Sauty de Chalon A, Teo Z, Park DJ, Odefrey FA, Hopper JL, Southey MC (2010) Are PALB2 mutations associated with increased risk of male breast cancer? Breast Cancer Res Treat 121(1):253-255
43. Lord CJ, Ashworth A (2008) Targeted therapy for cancer using PARP inhibitors. Curr Opin Pharmacol 8(4):363-369